Neurogene Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3
Neurogene Inc. (NGNE) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 of $0 for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-04.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3 · last filed 2014-11-04
- Neurogene Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2014-09-30 was $0.00.
- Neurogene Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2014-06-30 was $0.00.
- Neurogene Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2014-03-31 was $0.00.
- Neurogene Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2013-03-31 was $0.00.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 9 month |
|---|---|---|---|
| 2014-09-30 | $0.00 10-Q · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-13 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |